XML 15 R25.htm IDEA: XBRL DOCUMENT v2.4.0.6
NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details) (USD $)
9 Months Ended 1 Months Ended
Sep. 30, 2012
Dec. 31, 2011
Sep. 30, 2011
Dec. 31, 2010
Nov. 30, 2012
Subsequent event
Nature of Operations          
Cash and cash equivalents $ 17,837,000 $ 24,449,000 $ 27,675,000 $ 29,495,000  
Period for which cash and cash equivalents are sufficient to meet anticipated short-term working capital needs and to fund our on-going sapacitabine clinical trials 12 months        
NATURE OF OPERATIONS AND BASIS OF PRESENTATION          
Grant awarded from UK Government's Biomedical Catalyst         $ 1,900,000